Corden Pharma is a global CDMO making APIs, peptides, lipids, and sterile injectables. Learn about its services, sites, leadership, and who it serves.
Corden Pharma (branded CordenPharma) is a privately held contract development and manufacturing organization, or CDMO, that produces active pharmaceutical ingredients and finished drug products for other pharmaceutical and biotech companies. It does not sell medicines directly to patients, and it does not sell peptides or research chemicals to consumers. Its platforms span small molecules, peptides, oligonucleotides, lipids, carbohydrates, highly potent APIs, and sterile injectables.
What CordenPharma Does as a CDMO
A CDMO takes on the manufacturing work that drug developers either cannot or prefer not to do in-house. CordenPharma handles process development, scale-up, analytical testing, regulatory documentation, and commercial production under GMP conditions.
That work usually covers the full lifecycle of a drug:
- Early development — route scouting, process optimization, and small-scale GMP batches for clinical trials.
- Clinical supply — manufacturing, packaging, and release testing for Phase I through Phase III studies.
- Commercial manufacturing — large-scale API production and sterile fill-finish for marketed products.
CordenPharma serves large pharmaceutical companies as well as smaller biotechs that need a partner with facilities already inspected by agencies such as the FDA and EMA.
CordenPharma Technology Platforms
The company markets several distinct technology areas rather than a single product line. Each platform needs different equipment, chemistry, and quality controls.
| Platform | What It Covers | Typical Applications |
|---|---|---|
| Small molecule APIs | Synthetic drug substances and intermediates | Oral and injectable medicines |
| Peptides | Solid- and liquid-phase GMP peptide synthesis | Metabolic, oncology, and diagnostic peptides |
| Oligonucleotides | Antisense and siRNA manufacturing | Genetic and rare-disease medicines |
| Lipids | Lipid nanoparticles and pharmaceutical excipients | mRNA vaccines and delivery systems |
| Carbohydrates | Complex carbohydrate chemistry | Glycobiology and vaccine components |
| Sterile injectables | Aseptic fill-finish and lyophilization | Vials, syringes, and other injectable formats |
| HPAPIs | Highly potent compounds with containment | Oncology and other potent therapies |
Lipid production drew wide attention during the COVID-19 pandemic, when the company supplied lipid components used in mRNA vaccine delivery. Peptide capacity has expanded sharply as demand for GLP-1 and metabolic disease treatments has grown.
Corden Pharma Locations and Global Footprint
CordenPharma runs a network of development and manufacturing sites across Europe and the United States. The company has expanded that footprint repeatedly through both capital projects and acquisitions.
- United States: Boulder, Colorado, which handles small molecule and peptide work, and North Augusta, South Carolina, home to AmbioPharm, the peptide-focused business CordenPharma acquired in 2020.
- Germany and Switzerland: API development, manufacturing, and corporate functions.
- Italy, France, and Belgium: additional API, peptide, and sterile manufacturing capacity.
The full corden pharma locations list changes as plants are added or expanded, so the company's own site remains the most reliable source for current details.
Leadership, Ownership, and Financial Reporting
CordenPharma is owned by International Chemical Investors Group (ICIG), a private industrial holding company. Searches for the corden pharma ceo typically lead to Dr. Michael Quirmbach, who has served as President and CEO of CordenPharma since 2019.
Because the company is privately held, it does not publish a corden pharma annual report in the way a publicly traded drugmaker does. Financial information is generally limited to press releases, ICIG disclosures, and trade-press coverage of expansions and acquisitions.
Corporate news, hiring posts, and conference appearances appear regularly on the company's corden pharma linkedin page, which is often the fastest public source for updates.
Peptide Manufacturing and the Competitive Landscape
Peptide APIs are one of CordenPharma's strategic growth areas. The corden peptide business covers research-scale synthesis through commercial GMP production, including long-chain and modified peptides that are difficult to make at scale.
Several specialist peptide companies compete in the same space, including Bachem, PolyPeptide Group, and other CDMOs with dedicated peptide suites. Choosing between them usually comes down to capacity, analytical capability, regulatory history, and timeline.
Peptide chemistry also confuses newcomers. A plain-language explainer on what is peptide chemistry can help readers understand why chain length, purity targets, and purification steps drive both cost and manufacturing difficulty.
What CordenPharma Does Not Do
CordenPharma is a business-to-business manufacturer. It does not run a consumer storefront, and it does not sell APIs, peptides, or research chemicals to individuals.
Some third-party websites use the Corden or CordenPharma name in ways that imply an official connection. Those listings deserve caution, because the company's output goes to licensed pharmaceutical clients under strict supply agreements.
Nothing on this page is medical advice. Anyone with questions about a peptide or injectable medicine should consult a licensed healthcare professional rather than rely on vendor marketing.
Frequently Asked Questions
Is Corden Pharma a drug company or a CDMO?
CordenPharma is a contract development and manufacturing organization, not a company that sells its own branded medicines. It develops and manufactures APIs and finished drug products on behalf of pharmaceutical and biotech clients under GMP conditions. Its platforms include small molecules, peptides, oligonucleotides, lipids, carbohydrates, high-potency APIs, and sterile injectables.
Does Corden Pharma sell peptides to the public?
No. CordenPharma is a business-to-business manufacturer and does not sell peptides, APIs, or research chemicals to individual consumers. Any consumer-facing website claiming to offer Corden or CordenPharma peptides is not an authorized sales channel. Patients should talk with a licensed healthcare professional about any peptide product they are considering.
Who owns Corden Pharma and who runs it?
CordenPharma is privately held by International Chemical Investors Group (ICIG), an industrial holding company. Dr. Michael Quirmbach has served as President and CEO of CordenPharma since 2019. Because the company is private, detailed financial statements are not released the way they are for publicly traded drugmakers.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.